InfraReDx, Inc. headquartered in Burlington, Massachusetts, is a privately-funded company developing a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to detect lipid-rich plaques in the coronary arteries, which are suspected to be vulnerable plaque, the most frequent cause of heart attacks. The mission of InfraReDx, Inc. is to develop novel, photonic-based medical devices that will help improve the diagnosis and treatment of various diseases.  Clinical research studies are underway to determine the ability of the InfraReDx system to determine the chemical composition of plaques in patients undergoing cardiac catheterization.